1
|
Shakhakarmi K, Seo JE, Lamichhane S, Thapa C, Lee S. EGF, a veteran of wound healing: highlights on its mode of action, clinical applications with focus on wound treatment, and recent drug delivery strategies. Arch Pharm Res 2023; 46:299-322. [PMID: 36928481 DOI: 10.1007/s12272-023-01444-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2022] [Accepted: 03/09/2023] [Indexed: 03/18/2023]
Abstract
Epidermal growth factor (EGF) has been used in wound management and regenerative medicine since the late 1980s. It has been widely utilized for a long time and still is because of its excellent tolerability and efficacy. EGF has many applications in tissue engineering, cancer therapy, lung diseases, gastric ulcers, and wound healing. Nevertheless, its in vivo and during storage stability is a primary concern. This review focuses on the topical use of EGF, especially in chronic wound healing, the emerging use of biomaterials to deliver it, and future research possibilities. To successfully deliver EGF to wounds, a delivery system that is proteolytically resistant and stable over the long term is required. Biomaterials are an area of interest for the development of such systems. These systems may be used in non-healing wounds such as diabetic foot ulcers, pressure ulcers, and burns. In these pathologies, EGF can reduce the risk of amputation of the lower extremities, as it accelerates the wound healing process. Furthermore, appropriate delivery system would also stabilize and control the EGF release profile in a wound. Several in vitro and in vivo studies have already proven the efficacy of such systems in the above-mentioned types of wounds. Moreover, several formulations such as ointments and intralesional injections are already available on the market. However, these products are still problematic in terms of inadequate diffusion of EGF, low bioavailability storage conditions, and shelf-life. This review discusses the nano formulations comprising biomaterials infused with EGF which could be a promising delivery system for chronic wound healing in the future.
Collapse
Affiliation(s)
| | - Jo-Eun Seo
- College of Pharmacy, Keimyung University, Daegu, 704-701, Republic of Korea
| | | | - Chhitij Thapa
- College of Pharmacy, Keimyung University, Daegu, 704-701, Republic of Korea
| | - Sangkil Lee
- College of Pharmacy, Keimyung University, Daegu, 704-701, Republic of Korea.
| |
Collapse
|
2
|
Torres-Figueroa AV, Pérez-Martínez CJ, Encinas JC, Burruel-Ibarra S, Silvas-García MI, García Alegría AM, del Castillo-Castro T. Thermosensitive Bioadhesive Hydrogels Based on Poly( N-isopropylacrilamide) and Poly(methyl vinyl ether- alt-maleic anhydride) for the Controlled Release of Metronidazole in the Vaginal Environment. Pharmaceutics 2021; 13:pharmaceutics13081284. [PMID: 34452245 PMCID: PMC8402040 DOI: 10.3390/pharmaceutics13081284] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Revised: 08/11/2021] [Accepted: 08/13/2021] [Indexed: 12/27/2022] Open
Abstract
The development of thermosensitive bioadhesive hydrogels as multifunctional platforms for the controlled delivery of microbicides is a valuable contribution for the in situ treatment of vagina infections. In this work, novel semi-interpenetrating network (s-IPN) hydrogels were prepared by the entrapment of linear poly(methyl vinyl ether-alt-maleic anhydride) (PVME-MA) chains within crosslinked 3D structures of poly(N-isopropylacrylamide) (PNIPAAm). The multifunctional platforms were characterized by Fourier transform infrared spectroscopy, scanning electron microscopy, thermal techniques, rheological analysis, swelling kinetic measurements, and bioadhesion tests on porcine skin. The hydrogels exhibited an interconnected porous structure with defined boundaries. An elastic, solid-like behavior was predominant in all formulations. The swelling kinetics were strongly dependent on temperature (25 °C and 37 °C) and pH (7.4 and 4.5) conditions. The s-IPN with the highest content of PVME-MA displayed a significantly higher detachment force (0.413 ± 0.014 N) than the rest of the systems. The metronidazole loading in the s-IPN improved its bioadhesiveness. In vitro experiments showed a sustained release of the antibiotic molecules from the s-IPN up to 48 h (94%) in a medium simulating vaginal fluid, at 37 °C. The thermosensitive and bioadhesive PNIPAAm/PVME-MA systems showed a promising performance for the controlled release of metronidazole in the vaginal environment.
Collapse
Affiliation(s)
- Ana V. Torres-Figueroa
- Departamento de Investigación en Polímeros y Materiales, Universidad de Sonora, Hermosillo 83000, Mexico; (A.V.T.-F.); (J.C.E.); (S.B.-I.)
| | - Cinthia J. Pérez-Martínez
- Departamento de Ciencias Químico Biológicas, Universidad de Sonora, Hermosillo 83000, Mexico; (C.J.P.-M.); (A.M.G.A.)
| | - J. Carmelo Encinas
- Departamento de Investigación en Polímeros y Materiales, Universidad de Sonora, Hermosillo 83000, Mexico; (A.V.T.-F.); (J.C.E.); (S.B.-I.)
| | - Silvia Burruel-Ibarra
- Departamento de Investigación en Polímeros y Materiales, Universidad de Sonora, Hermosillo 83000, Mexico; (A.V.T.-F.); (J.C.E.); (S.B.-I.)
| | - María I. Silvas-García
- Departamento de Investigación y Posgrado en Alimentos, Universidad de Sonora, Hermosillo 83000, Mexico;
| | - Alejandro M. García Alegría
- Departamento de Ciencias Químico Biológicas, Universidad de Sonora, Hermosillo 83000, Mexico; (C.J.P.-M.); (A.M.G.A.)
| | - Teresa del Castillo-Castro
- Departamento de Investigación en Polímeros y Materiales, Universidad de Sonora, Hermosillo 83000, Mexico; (A.V.T.-F.); (J.C.E.); (S.B.-I.)
- Correspondence:
| |
Collapse
|
3
|
Ramineni SK, Dziubla TD, Cunningham LL, Puleo DA. Local delivery of imiquimod in hamsters using mucoadhesive films and their residence time in human patients. Oral Surg Oral Med Oral Pathol Oral Radiol 2014; 118:665-73. [PMID: 25457885 DOI: 10.1016/j.oooo.2014.08.015] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2014] [Revised: 08/13/2014] [Accepted: 08/25/2014] [Indexed: 10/24/2022]
Abstract
OBJECTIVE To investigate the ability of mucoadhesive films to locally deliver an immune response modifier (imiquimod) to oral mucosa. STUDY DESIGN After determining the residence time of films in hamster cheek pouches, drug-loaded films and commercially available imiquimod cream were tested for localization of drug in mucosal tissue. The residence time of drug-free films at different locations was also tested in humans. RESULTS Mucoadhesive films delivered imiquimod to the buccal mucosa with no measureable amounts in blood. In contrast, although the cream formulation resulted in higher tissue levels, it also led to significant systemic distribution of imiquimod. In humans, the films resided on tissue for up to 4 hours, increasing in the order of tongue < cheek < gingiva. CONCLUSION Preclinical findings of localized imiquimod delivery in animals and residence in humans support future investigations of the mucoadhesive system in controlled clinical trials for treating oral precancerous lesions.
Collapse
Affiliation(s)
- Sandeep K Ramineni
- Department of Biomedical Engineering, University of Kentucky, Lexington, KY, USA
| | - Thomas D Dziubla
- Department of Chemical and Materials Engineering, University of Kentucky, Lexington, KY, USA
| | | | - David A Puleo
- Department of Biomedical Engineering, University of Kentucky, Lexington, KY, USA.
| |
Collapse
|
4
|
Zhou W, Zhao M, Zhao Y, Mou Y. A fibrin gel loaded with chitosan nanoparticles for local delivery of rhEGF: preparation and in vitro release studies. JOURNAL OF MATERIALS SCIENCE. MATERIALS IN MEDICINE 2011; 22:1221-30. [PMID: 21445654 DOI: 10.1007/s10856-011-4304-9] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/01/2010] [Accepted: 03/21/2011] [Indexed: 05/24/2023]
Abstract
Recombinant human epidermal growth factor (rhEGF) is known to stimulate cell proliferation and accelerate wound healing. Direct delivery of rhEGF at the wound site in a sustained and controllable way without loss of bioactivity would enhance its biological effects. The aim of this study was to prepare a novel local delivery system for the sustained and controllable release of rhEGF, a fibrin gel loaded with chitosan nanoparticles. First, rhEGF-loaded chitosan nanoparticles were prepared and characterized, and these showed an ability to protect rhEGF from proteolysis. The prepared nanoparticles were then incorporated into a fibrin gel matrix during polymerization. In vitro release studies showed that the fibrin gel loaded with rhEGF/chitosan nanoparticles could achieve a more sustained release of rhEGF than either chitosan nanoparticles or an unloaded fibrin gel. Additionally, the release rate could be controlled by altering the contents of fibrinogen and thrombin in this composite delivery system. The bioactivity of the released rhEGF was determined by assessing its ability to stimulate the proliferation of BALB/c 3T3 cells, and the results showed that rhEGF bioactivity was not affected during the preparation process and could be maintained for at least 7 days. This novel delivery system may have great potential applications in the local administration of rhEGF.
Collapse
Affiliation(s)
- Wenjun Zhou
- Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, The First Affiliated Hospital of Chongqing Medical University, No. 1, Youyi Road, Yu Zhong District, Chongqing, 400016, China
| | | | | | | |
Collapse
|
5
|
Asane GS, Nirmal SA, Rasal KB, Naik AA, Mahadik MS, Rao YM. Polymers for mucoadhesive drug delivery system: a current status. Drug Dev Ind Pharm 2009; 34:1246-66. [PMID: 18720139 DOI: 10.1080/03639040802026012] [Citation(s) in RCA: 83] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
To overcome the relatively short gastrointestinal (GI) time and improve localization for oral controlled or sustained release drug delivery systems, bioadhesive polymers that adhere to the mucin/epithelial surface are effective and lead to significant improvement in oral drug delivery. Improvements are also expected for other mucus-covered sites of drug administration. Bioadhesive polymers find application in the eye, nose, and vaginal cavity as well as in the GI tract, including the buccal cavity and rectum. This article lays emphasis mainly on mucoadhesive polymers, their properties, and their applications in buccal, ocular, nasal, and vaginal drug delivery systems with its evaluation methods.
Collapse
Affiliation(s)
- G S Asane
- Department of Pharmaceutics, Pravara Rural College of Pharmacy, Loni, M.S., India.
| | | | | | | | | | | |
Collapse
|
6
|
Abstract
Buccal formulations have been developed to allow prolonged localised therapy and enhanced systemic delivery. The buccal mucosa, however, while avoiding first-pass effects, is a formidable barrier to drug absorption, especially for biopharmaceutical products (proteins and oligonucleotides) arising from the recent advances in genomics and proteomics. The buccal route is typically used for extended drug delivery, so formulations that can be attached to the buccal mucosa are favoured. The bioadhesive polymers used in buccal drug delivery to retain a formulation are typically hydrophilic macro-molecules containing numerous hydrogen bonding groups. Newer second-generation bioadhesives have been developed and these include modified or new polymers that allow enhanced adhesion and/or drug delivery, in addition to site-specific ligands such as lectins. Over the last 20 years a wide range of formulations has been developed for buccal drug delivery (tablet, patch, liquids and semisolids) but comparatively few have found their way onto the market. Currently, this route is restricted to the delivery of a limited number of small lipophilic molecules that readily cross the buccal mucosa. However, this route could become a significant means for the delivery of a range of active agents in the coming years, if the barriers to buccal drug delivery are overcome. In particular, patient acceptability and the successful systemic delivery of large molecules (proteins, oligonucleotides and polysaccharides) via this route remains both a significant opportunity and challenge, and new/improved technologies may be required to address these.
Collapse
Affiliation(s)
- John D Smart
- School of Pharmacy and Biomolecular Sciences, University of Brighton, Lewes Road, Brighton BN2 4GJ, UK.
| |
Collapse
|